Publications scientifiques et présentations

Ces publications scientifiques et présentations sont proposées à des fins de formation uniquement. Elles peuvent mentionner ou discuter des produits de DBV Technologies en cours de développement, et qui ne sont approuvés pour commercialisation par aucune autorité règlementaire ou de santé dans aucun pays du monde.

Publications importantes

Petroni D, Bégin P, Bird JA, et al.
Varying Doses of Epicutaneous Immunotherapy With Viaskin Milk vs Placebo in Children With Cow’s Milk Allergy: A Randomized Clinical Trial
JAMA Pediatr. 2024; 178(4): 345–353. PMID: 38407859 | doi: 10.1001/jamapediatrics.2023.6630
Dupont C, Burks AW, Fleischer DM, Bee KJ, Chainani S, Sampson HA
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
Expert Rev Clin Immunol. Published online February 14, 2024. PMID: 38323337 | doi:10.1080/1744666X.2024.2315221
Stukus DR, Gupta R, Mack D, et al.
Epicutaneous immunotherapy with Viaskin™ Peanut in toddlers: a plain language summary
Immunotherapy. 2024;16(1):5-13. PMID: 38112107 | doi:10.2217/imt-2023-0201
Hervé PL, Dioszeghy V, Matthews K, Bee KJ, Campbell DE, Sampson HA
Recent advances in epicutaneous immunotherapy and potential applications in food allergy
Front Allergy. 2023;4:1290003. PMID: 37965375 | doi:10.3389/falgy.2023.1290003
Matthew Greenhawt, M.D., Sayantani B. Sindher, M.D., Julie Wang, M.D., et al.
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
New England Journal of Medicine 2023; 388:1814-1815 | doi:10.1056/NEJMe2301157
Pongracic JA, Gagnon R, et al.
Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results
J Allergy Clin Immunol Pract. 2021. Nov 27;S2213-2198(21)01295-2. | doi:10.1016/j.jaip.2021.11.017
Bégin P, Bird JA, et al.
Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy
Allergy. 2021. Dec;76(12):3835-3838. | doi: 10.1111/all.15083.
Remington BC, Koppelman SJ, et al.
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Allergy. 2021. Oct;76(10):3223-3226. | doi: 10.1111/all.14973.
Brown-Whitehorn TF, de Blay F, et al.
Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):524-526. | doi: 10.1016/j.jaip.2020.08.017.
DunnGalvin A, Fleischer DM, et al.
Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies
The Journal of Allergy and Clinical Immunology: In Practice. 2021. Jan;9(1):216-224.e1. | doi: 10.1016/j.jaip.2020.08.015.
Remington BC, Campbell DE, et al.
Post hoc analysis of epicutaneous immunotherapy for peanut allergy phase 3 results
Relevance for exposure through restaurant meals. Annals of Allergy, Asthma & Immunology. 2021. Feb126(2):208-209. | doi: 10.1016/j.anai.2020.11.015.
Greenhawt M, Kim EH, et al.
Improvements in eliciting dose across baseline sensitivities following 12 months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years
The Journal of Allergy and Clinical Immunology: In Practice. 2020;S2213-2198(20)30526-2. PMID: 32502548. | doi:10.1016/j.jaip.2020.05.030.
Fleischer DM, Shreffler WG, et al.
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results
The Journal of Allergy and Clinical Immunology. 2020. | doi:10.1016/j.jaci.2020.06.028.
Fleischer DM, Chinthrajah S, et al.
An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial
Allergy & Asthma Proceedings. 2020;41:1-10. PMID: 32539908. | doi:10.2500/aap.2020.41.200047.
Fleischer DM, Spergel JM, et al.
Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy
Allergy & Asthma Proceedings. 2020;41:278-284. PMID: 32517847. | doi:10.2500/aap.2020.41.200045
Fleischer DM, Greenhawt M, et al.
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy
The PEPITES Randomized Clinical Trial. JAMA. 2019;321:946-955. PMID: 30794314. | doi:10.1001/jama.2019.1113.
Sampson HA, Shreffler WG, et al.
Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity
A Randomized Clinical Trial. JAMA. 2017;318:1798-1809. PMID: 29136445. | doi:10.1001/jama.2017.16591.
Get the Quarterly Newsletter from DBV Technologies Medical Affairs & Clinical Development
S’inscrire

Présentations Récentes

Ces résumés ont été approuvés pour présentation à un congrès médical et n’ont pas été soumis à une revue complète par des pairs.

European Academy of Allergy and Clinical Immunology (EAACI) 2024 Annual Meeting, May 31-June 3, 2024:

Presentation:

  • Reactions due to Accidental Peanut Consumption During Epicutaneous Immunotherapy for Peanut Allergy in Toddlers: Valencia, Spain – Arends N, Vogelberg C, Turner PJ, et al. [Poster]

American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting, February 23-26, 2024:

Poster Presentation:

  • Long-Term Safety Results of Epicutaneous Immunotherapy (EPIT) With Viaskin Peanut in Peanut-Allergic Children Aged 4 Through 11 Years in the Phase 3 PEOPLE Study: Washington, DC – Fleischer DM, Ford LS, Sussman G, et al. [Poster]

American College of Allergy, Asthma & Immunology (ACAAI), November 9-13, 2023:

Oral Presentation:

  • EPOPEX, Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-allergic Toddlers: 1-year Open-Label Extension to EPITOPE – Matthew Greenhawt, MD [Abstract LB010]

European Academy of Allergy and Clinical Immunology (EAACI), June 9-11, 2023:

Poster Presentations:

  • Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1 Through 3 Years With and Without Concomitant Asthma in the EPITOPE Study—George Du Toit, et al. [Poster]
  • Health State Utilities in Children with Peanut Allergy and Their Caregivers: A United Kingdom Vignette Study—Marieke Schurer, et al. [Poster]
  • Characteristics and Current Management Strategies of Children Diagnosed with Peanut Allergy in the United Kingdom—Mich Erlewyn-Lajeunesse, et al. [Poster]

Eastern Allergy Conference (EAC), June 1-4, 2023:

Poster Presentations:

  • Impact of Duration of Wear on Efficacy of Epicutaneous Immunotherapy with Viaskin Peanut in Toddlers Aged 1 Through 3 Years During the Phase 3 EPITOPE Study –Todd D. Green, Katharine J. Bee, Henry T. Bahnson, et al. [Poster]

American Academy of Allergy, Asthma & Immunology (AAAAI) 2023 Annual Meeting:

Poster Presentations:

  • Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Concomitant Food Allergies in the EPITOPE Study –David Fleischer, M.D. [Poster 082]
  • Efficacy and Safety of Epicutaneous Immunotherapy for Peanut Allergy in Subjects Aged 1-3 Years With and Without Atopic Dermatitis in the EPITOPE Study — Amy Scurlock, M.D. [Poster 085]
Retour en haut